Phenolic Acid Derivatives for Ischemic Stroke Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cerebral ischemic stroke are inadequate, with many patients missing the treatment window, experiencing disability, and lacking effective therapies for sequelae, and there is a need for new drugs that can inhibit inflammation and improve neurological outcomes.
Innovation Solution
The use of phenolic acids derivatives, or their pharmaceutically acceptable salts, optical isomers, hydrates, or prodrugs, to inhibit astrocyte and microglia proliferation, reduce pro-inflammatory factors (TNF-α, IL-1β, IL-6, iNOS, COX2, and HIF-1α) expression, and alleviate inflammatory responses, thereby treating cerebral ischemic stroke.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thrombolytic therapy or intravascular thrombectomy is used for cerebral ischemic stroke, then treatment effectiveness is improved, but treatment window limitation and disability risk remain
Solution Approach 1:
The phenolic acids derivative is administered before the ischemic stroke occurs (prophylactic treatment). The drug pre-activates protective pathways including HIF-1α signaling and anti-inflammatory responses, so that when ischemia occurs, the brain is already in a protected state. This eliminates the need for rapid intervention within a narrow treatment window, as the protective effect is established in advance.
2Reliability
If thrombolytic therapy or intravascular thrombectomy is used for cerebral ischemic stroke, then treatment effectiveness is improved, but disability and condition exacerbation still occur
Solution Approach 1:
The phenolic acids derivative establishes protective mechanisms before ischemic injury occurs. It pre-activates HIF-1α signaling pathways and upregulates anti-inflammatory responses, creating a cushion of protection against subsequent ischemic damage. This cushioning effect prevents disability and mitigates ischemia-reperfusion injury even when standard thrombolytic therapy is administered.
Solution Approach 2:
The drug converts the harmful inflammatory response that normally follows ischemic stroke into a beneficial protective response. By pre-activating HIF-1α and anti-inflammatory pathways, the drug transforms the post-ischemic inflammatory cascade from a damaging force into a controlled, protective response that limits tissue damage and prevents disability.
3Reliability
If current treatments are used for cerebral ischemic stroke, then acute phase management is addressed, but no effective treatment exists for sequelae
Solution Approach 1:
The phenolic acids derivative provides multi-phase protection covering the entire spectrum of ischemic stroke pathology. It simultaneously addresses acute phase management through HIF-1α activation and prevents sequelae through sustained anti-inflammatory effects and inhibition of astrocyte/microglia proliferation. This single agent thus provides both acute rescue and long-term protective benefits, eliminating the need for separate acute and rehabilitative treatments.
Data Source
AI summary
A phenolic acids derivative can be used in treating ischemic stroke. Specifically, a compound represented by the following formula (I), or a pharmaceutically acceptable salts thereof, or an optical isomer, a hydrate, a solvate, or a prodrug thereof for can be used in preparing a pharmaceutical composition for the treating and/or relieving ischemic stroke.